Mayo Clinic Florida, Jacksonville, FL 32224, USA.
Breast. 2010 Apr;19(2):92-6. doi: 10.1016/j.breast.2009.12.001. Epub 2010 Jan 15.
Postmenopausal women with osteoporosis/osteopenia are at increased risk of fracture. Aromatase inhibitors further increase bone loss in these patients. This study evaluates whether zoledronic acid prevents the bone loss expected when these patients initiate letrozole.
Postmenopausal women with estrogen and/or progesterone receptor-positive breast cancer and a bone mineral density (BMD) T-score <-2.0 were given letrozole 2.5mg/vitamin D 400 international units daily, calcium 500mg twice daily, and 4mg zoledronic acid every 6 months. The BMD was assessed at baseline and 1 year. The primary endpoint was the mean change in lumbar spine (LS) BMD at 1 year.
Forty-six patients completed 1 year of treatment. LS BMD increased by 2.66% (p=0.01), femoral neck (FN) by 4.81% (p=0.01), and any measured endpoint by 4.55% (p=0.0052).
Zoledronic acid prevents bone loss in postmenopausal women with osteoporosis/osteopenia starting letrozole and is associated with improvements in BMD.
患有骨质疏松症/骨量减少的绝经后妇女骨折风险增加。芳香化酶抑制剂会进一步增加这些患者的骨质流失。本研究评估唑来膦酸是否可以预防开始使用来曲唑时这些患者预期的骨质流失。
患有雌激素和/或孕激素受体阳性乳腺癌且骨密度（BMD）T 评分<-2.0 的绝经后妇女每日给予来曲唑 2.5mg/维生素 D 400 国际单位、钙 500mg 每日两次和唑来膦酸 4mg，每 6 个月一次。在基线和 1 年时评估 BMD。主要终点是 1 年时腰椎（LS）BMD 的平均变化。
46 例患者完成了 1 年的治疗。LS BMD 增加了 2.66%（p=0.01），股骨颈（FN）增加了 4.81%（p=0.01），任何测量终点都增加了 4.55%（p=0.0052）。
唑来膦酸可预防开始使用来曲唑的骨质疏松/骨量减少绝经后妇女的骨质流失，并与 BMD 的改善相关。
